Immunotherapy of MDS: you can run, but you can't hide

The hypomethylating agent decitabine induces expression of the cancer testis antigen NY-ESO-1 in the myeloid cells of patients with myelodysplastic syndrome (MDS).  MDS patients treated with decitabine and an NY-ESO-1 vaccine developed NY-ESO-1-specific T cell responses directed against their abnormal myeloid cells, raising hopes for combinatorial immunotherapy of this disease.

from Cancer via ola Kala on Inoreader http://ift.tt/2BQRJ9z
via IFTTT